CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Sees Large Growth in Short Interest

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) was the recipient of a significant increase in short interest in January. As of January 15th, there was short interest totalling 6,000 shares, an increase of 87.5% from the December 31st total of 3,200 shares. Based on an average daily trading volume, of 14,500 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.1% of the company’s shares are short sold.

CollPlant Biotechnologies Stock Performance

Shares of NASDAQ CLGN traded up $0.08 during mid-day trading on Wednesday, reaching $3.83. 1,844 shares of the company’s stock were exchanged, compared to its average volume of 6,796. The firm has a market capitalization of $43.80 million, a price-to-earnings ratio of -2.48 and a beta of 0.63. CollPlant Biotechnologies has a 52-week low of $3.24 and a 52-week high of $6.75. The company’s 50-day moving average is $3.95 and its 200-day moving average is $4.38.

CollPlant Biotechnologies (NASDAQ:CLGN) last announced its earnings results on Wednesday, November 27th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.01). CollPlant Biotechnologies had a negative return on equity of 77.05% and a negative net margin of 2,680.00%. During the same quarter in the previous year, the business posted ($0.38) EPS. As a group, equities analysts predict that CollPlant Biotechnologies will post -1.44 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CollPlant Biotechnologies

A hedge fund recently raised its stake in CollPlant Biotechnologies stock. Villere ST Denis J & Co. LLC boosted its stake in shares of CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) by 24.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 484,867 shares of the company’s stock after purchasing an additional 95,000 shares during the quarter. Villere ST Denis J & Co. LLC owned approximately 4.23% of CollPlant Biotechnologies worth $2,407,000 as of its most recent SEC filing. 21.69% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. D. Boral Capital restated a “buy” rating and set a $14.00 price objective on shares of CollPlant Biotechnologies in a research report on Wednesday, November 27th. HC Wainwright restated a “buy” rating and set a $11.00 price target on shares of CollPlant Biotechnologies in a report on Friday, November 29th.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.